The Myval transcatheter heart valve (THV) series was non inferior versus contemporary THVs in patients with symptomatic severe native aortic stenosis at 1-year post-procedurally, according to the latest LANDMARK trial follow-up. The results were presented Wednesday at EuroPCR 2025 in Paris, by Patrick W. Serruys, MD, PhD, from the University of Galway, Ireland, and are line with the earlier 30-day findings from the study, originally published in 2024 in the Lancet, proving non-inferiority versus Sapien (Edwards Lifesciences) and Evolut (Medtronic) series THVs. LANDMARK randomized 768 patients with symptomatic severe native aortic stenosis in a 1:1 fashion (384 given Myval THV series [Meril Life], and 384 a contemporary device – with either a Sapien [n=192] or an Evolut device [n=192]) across 31 centers in 16 countries, encompassing Europe, New Zealand and Brazil. In the current 1-year follow-up, 49 patients in the Myval THV group experienced the clinical efficacy endpoint (a composite of death, stroke or procedure/valve-related hospitalization) per VARC-3, versus 50 in the contemporary THV series group (13% vs 13.1%, hazard ratio [HR]: 0.97; 95% confidence interval [CI]: 0.66-1.44; p-value log-rank = 0.90, p for noninferiority = < 0.0001). No significant differences were observed in any of the constituent endpoints individually, Dr. Serruys also reported, with a 7.2% all-cause mortality rate in the Myval group vs 7.1% given contemporary THVs (risk difference = 0.1; 95% CI: -3.5 – 3.7; p = 1), a 5.7% vs 3.4% rate of stroke, respectively (risk difference = 2.3; 95% CI: -0.6 – 5.2; p = 0.22) and a 4.3% vs 5.4% rate of procedure/ valve-related hospitalization (risk difference = -1.1; 95% CI: -4.1 – 1.9; p = 0.61). “Echocardiographic outcomes as well as quality-of-life outcomes were comparable between the two arms,” added Dr. Serruys, who also reported ties with the Myval THV series’ manufacturer. Follow-up of LANDMARK patients is planned for up to 10 years to evaluate the long-term performance and durability of the device, he said. Image Credit: Copyright EuroPCR 2025 Image Caption: Patrick W. Serruys, MD, PhD, speaks during a press conference on Tuesday at EuroPCR Congress 2025 in Paris.